Scientists found a protein called GPR146 that acts like a messenger between your fat cells and liver. When this protein is active, it tells fat cells to store more fat and release more fatty acids into the bloodstream. These fatty acids then travel to the liver and build up there, causing a condition called fatty liver disease. In mouse studies, turning off this protein protected animals from gaining weight and developing fatty livers. This discovery could lead to new treatments for people with metabolic dysfunction-associated fatty liver disease, a growing health problem with few treatment options.
The Quick Take
- What they studied: How a protein called GPR146 in fat tissue communicates with the liver and causes fat to build up in liver cells
- Who participated: Laboratory mice with different genetic modifications, plus human genetic data from large population studies to confirm the protein’s role in liver disease
- Key finding: Mice without the GPR146 protein gained less weight and had much less fat buildup in their livers, even when eating a high-fat diet. The protein works by making fat cells store more fat and release more fatty acids into the blood.
- What it means for you: This research suggests that blocking GPR146 might be a new way to treat fatty liver disease in humans. However, this is early-stage research in mice, so it will take several more years of testing before any human treatments become available. Talk to your doctor about current proven ways to prevent fatty liver disease, like maintaining a healthy weight and limiting sugary foods.
The Research Details
This study combined several research approaches. First, scientists analyzed human genetic data from large populations to see if the GPR146 gene was linked to liver disease markers. Then they used laboratory mice with specially designed genetics to study what happens when GPR146 is removed. Some mice had the protein removed from all their fat tissue, while others had it removed only from their liver cells. This allowed researchers to figure out exactly where the protein does its damage. The mice were fed either normal or high-fat diets to see how GPR146 affected weight gain and liver fat accumulation.
The researchers also studied how GPR146 works at the cellular level. They examined fat cells in test tubes to understand the specific chemical signals the protein uses to control fat storage and fat release. This detailed molecular work helped explain the chain of events that leads to fatty liver disease.
This multi-layered approach—combining human genetics, whole-animal studies, and cellular experiments—makes the research more convincing because the findings were confirmed through different methods.
Understanding exactly how fatty liver disease develops is crucial because current treatment options are very limited. Most doctors can only recommend lifestyle changes like diet and exercise, which don’t work for everyone. By identifying GPR146 as a key player in the disease process, scientists have found a specific target that could be blocked with new medicines. The fact that the protein works in fat tissue rather than the liver itself was surprising and important—it means treating fatty liver disease might require targeting fat cells, not just the liver.
This research was published in Nature Communications, one of the world’s most respected scientific journals, which means it underwent rigorous peer review. The study’s strength comes from using multiple approaches to confirm findings: human genetic data, whole-animal experiments, and cellular studies all pointed to the same conclusion. The researchers were careful to test whether removing GPR146 from different tissues (fat versus liver) produced different results, which shows scientific rigor. However, this is mouse research, so results may not directly translate to humans. The study also didn’t test any actual drugs, only what happens when the protein is genetically removed.
What the Results Show
When researchers removed the GPR146 protein from mice, several protective effects occurred. Mice without GPR146 gained significantly less weight when eating a high-fat diet compared to normal mice. More importantly, their livers accumulated much less fat—the key problem in fatty liver disease. These benefits appeared whether the protein was removed from birth or removed later in life, suggesting the protein is important throughout life.
The mechanism behind these benefits became clear through detailed cellular studies. GPR146 works like a control switch in fat cells. When active, it sends signals that tell fat cells to store more fat and to break down existing fat faster, releasing fatty acids into the bloodstream. These fatty acids travel through the blood to the liver, where they accumulate as triglycerides (a type of fat). By removing GPR146, researchers essentially turned off this fat-releasing signal, so less fatty acid reached the liver.
Interestingly, the location of the protein mattered tremendously. When researchers removed GPR146 only from liver cells, it had almost no protective effect. But removing it specifically from fat tissue produced the full benefit. This discovery was crucial because it showed the disease process depends on communication from fat tissue to the liver, not on the liver’s own ability to process fat.
The human genetic analysis revealed that variations in the GPR146 gene were associated with higher levels of liver injury markers and inflammation markers in the blood. This suggests the protein’s role in fatty liver disease is relevant to human health, not just a mouse phenomenon. The researchers also found that GPR146 affects how fat cells develop and mature, controlling both how much fat they store and how readily they release it. This dual control—affecting both storage and release—makes GPR146 a particularly powerful regulator of fatty acid flow to the liver.
Fatty liver disease has been linked to obesity and metabolic problems for years, but scientists didn’t fully understand the specific proteins and signals involved. Previous research showed that fatty acids from fat tissue are a major source of liver fat, but the exact mechanisms controlling this process were unclear. This study fills that gap by identifying GPR146 as a specific control point. The finding that fat tissue communication with the liver is critical aligns with recent research showing that fat tissue acts as an endocrine organ—meaning it produces signals that affect distant organs like the liver. However, GPR146 appears to be a previously unrecognized player in this communication system.
The most important limitation is that this research was conducted in mice, not humans. Mouse metabolism differs from human metabolism in important ways, so results may not directly translate. The study removed GPR146 completely through genetic engineering, which is different from partially blocking it with a drug—the actual approach that would be used in human treatment. The researchers didn’t test any actual medications, only the effects of genetic removal. Additionally, the study focused on diet-induced obesity in mice; it’s unclear whether GPR146 plays the same role in fatty liver disease caused by other factors like alcohol use or viral infections. Finally, the study didn’t examine long-term effects or potential side effects of removing GPR146, which would be important considerations for any future drug development.
The Bottom Line
Based on this research, there are no new direct recommendations for patients right now, since this is early-stage research. However, the findings support existing medical advice: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, and limit alcohol consumption. These proven approaches reduce fatty liver disease risk. If you have been diagnosed with fatty liver disease or are at risk, work with your doctor on a personalized prevention plan. This research suggests that future drug treatments targeting GPR146 might become available, but that is likely several years away and would require extensive human testing first.
This research is most relevant to people with metabolic dysfunction-associated fatty liver disease (MASLD), people with obesity, and people with metabolic syndrome. It’s also important for people with a family history of liver disease. Healthcare providers treating liver disease should be aware of this potential new treatment target. However, this research is not yet ready to change clinical practice—it’s a foundational discovery that will guide future drug development. People without liver disease or metabolic problems don’t need to take action based on this research alone.
If GPR146-blocking drugs are developed, human clinical trials would likely take 5-10 years before any medication becomes available to patients. Even then, benefits would likely develop gradually over weeks to months of treatment, not immediately. For now, lifestyle changes like diet and exercise can produce noticeable improvements in liver health within 3-6 months for many people.
Want to Apply This Research?
- Track weekly weight and waist circumference measurements, plus daily food intake focusing on added sugar and processed food consumption. These metrics directly relate to the mechanisms GPR146 controls—fat storage and fatty acid release.
- Users can set goals to reduce high-fat and high-sugar foods, which decreases the fatty acids available for liver accumulation. The app could provide meal suggestions emphasizing whole foods, vegetables, and lean proteins while tracking progress toward weight loss targets.
- Establish a 12-week tracking cycle measuring weight, diet quality, and exercise frequency. Users should monitor for energy levels and general wellness as indirect indicators of metabolic improvement. For those with diagnosed fatty liver disease, coordinate with their healthcare provider to track liver function blood tests (ALT, AST) every 3-6 months.
This research describes early-stage laboratory findings in mice and does not represent approved human treatments. The discovery of GPR146’s role in fatty liver disease is scientifically interesting but not yet ready for clinical application. No drugs targeting GPR146 are currently available for human use. If you have been diagnosed with fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MASLD), consult with your healthcare provider about proven treatment options including lifestyle modifications, weight management, and appropriate medical monitoring. Do not make changes to your diet, exercise routine, or medications based solely on this research without discussing with your doctor. This information is for educational purposes only and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.